JUN 1 1 2001 I hereby certify that this to espondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Attn: Box Missing Parts Washington, D.C. 20231/on/ June 4, 2001 Printed name:

Docket No.: PC-0025 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Michael G. Walker

Title:

ANKYRIN REPEAT DOMAIN 2 PROTEIN VARIANT

Serial No.:

09/758,593

Filing Date:

January 10, 2001

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Commissioner for Patents **Attn: Box Missing Parts** Washington, D.C. 20231

RESPONSE TO NOTICE TO FILE MISSING PARTS, FILING DATE GRANTED AND NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

In response to the Notice to File Missing Parts of Application, Filing Date Granted and Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed by the United States Patent and Trademark Office on April 3, 2001, Applicants submit the following documents to complete the filing for the above-identified patent application:

- 1. Copy of Notice to File Missing Parts of Application, Filing Date Granted; and Notice to Comply with Raw Sequence Listing Error Report (6 pp.);
 - 2. Executed Declaration & Power of Attorney for United States Patent Application (3 pp.);
 - 3. Substitute Submission Under 37 CFR § 1.821-1.825 Sequence Listing (1 pg.);
 - 4. One Substitute computer-readable diskette containing Sequence Listing;
 - 5. Paper Copy of the Substitute Sequence Listing (7 pg.) and
 - 6. Return postcard.

Docket No.: PC-0025 CIP

Please charge the following fees to Deposit Account No. 09-0108:

Basic surcharge fee for filing the declaration:

\$ 130.00

Total fees charged to Deposit Account No. 09-0108:

\$ <u>130.00</u>

If the Patent Office determines that additional fees are due or that an excess fee has been paid, the Patent Office is authorized to debit or credit (respectively) **Deposit Account No. 09-0108.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

This response is enclosed in duplicate.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: Ame

David G. Streeter, Ph.D.


Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

3160 Porter Drive

Palo Alto, CA 94304

Tel: 650-855-0555 Fax: 650-849-8886



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE

WASHINGTON, D.C. 20231 WWW.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/758,593

01/10/2001

Michael G. Walker

PC-0025 CIP

INCYTE GENOMICS, INC. 3160 Porter Drive

Palo Alto, CA 94304

CONFIRMATION NO. 9627 FORMALITIES LETTER
OC000000005930203

Date Mailed: 04/03/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- □ To Purchase Patentin Software, call (703) 306-2600
- □ For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

06/13/2001 ETULU1 00000113 090108 09758593

01 FC:105 _____130.00 CH

Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE